Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458146 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
A Phase 2 study of Rheumatoid Arthritis, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT00458146: Completed Phase 2 study of Rheumatoid Arthritis, sponsored by Merrimack Pharmaceuticals.
NCT00458146 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 100 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00458146, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether MM-093 is safe and effective in the treatment of RA.
Conditions Studied
Interventions
- DRUG MM-093
Study Locations (20)
Florida
- Arthritis and Rheumatic Disease Specialties - Aventura
- Paddock Park Clinical Research - Ocala
- Arthritis Research of Florida, Inc. - Palm Harbor
- Sarasota Arthritis Research Center - Sarasota
Arizona
- East Valley Rheumatology & Osteoporosis - Gilbert
- Radiant Research - Scottsdale
Colorado
- National Jewish Medical and Research Center - Denver
- Denver Arthritis Clinic - Denver
Pennsylvania
- East Pennsylvania Rheumatology Association - Bethlehem
- Altoona Center for Clinical Research - Duncansville
Alabama
- Montgomery Rheumatology Associates - Montgomery
California
- Arthritis Medical Center of the Central Coast - Santa Maria
Connecticut
- New England Research Associates - Trumbull
Illinois
- Illinois Bone & Joint Institute - Morton Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00458146 record still lists
NCT00458146 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which MM-093 is the first listed.
NCT00458146 names 20 study sites across 14 states, led by Florida, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00458146 about?
NCT00458146 is a clinical study titled "A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis". The purpose of this study is to determine whether MM-093 is safe and effective in the treatment of RA.
What is the current status of trial NCT00458146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-02.
What conditions does trial NCT00458146 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00458146?
The interventions under investigation include: MM-093 (DRUG).
Who is sponsoring clinical trial NCT00458146?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00458146 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00458146's enrollment target sits among peer trials
100 117th of 197 higher than 78 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia